Boston Scientific has announced it has received FDA approval its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers, according to a news release.
The INGENIO and ADVANTIO pacemakers feature RightRate pacing technology designed to help treat chronotropic incompetence. In addition to RightRate, the INGENIO pacemaker features Respiratory Rate Trend, which monitors respiration.
"We are very pleased to receive FDA approval for these advanced devices, and excited about the potential they bring to our bradycardia business," said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group, in the release. "With these products, Boston Scientific embarks on a new era in pacing technology. The company's significant investments in the INGENIO platform have been focused on long-term innovation in pacing technologies, and are expected to support a comprehensive series of launches over the next several years to expand our pacing capabilities and help improve patient outcomes."
The first implant of the INGENIO pacemaker in the United States was performed by Bruce L. Wilkoff, MD, director of cardiac pacing and tachyarrhythmia devices at the Cleveland Clinic, on May 3.
Related Articles on FDA Approvals:
CurveBeam Receives FDA 510(k) Approval for the pedCAT 3D Foot and Ankle Scanner
Carestream Health Receives FDA Clearance for Mobile X-Ray System
NeuroMetrix Seeks FDA Approval for New Pain Therapy Device